AbbVie AndroGel Jury Verdict Targets 'Low T' Promotion
Executive Summary
In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.
You may also be interested in...
Liabilities Update: AbbVie Wins AndroGel Re-Trial; Actavis To Settle Out Of Testosterone MDL
For second time, judge finds problem with jury verdict against AbbVie; Bayer withdraws its appeal of Xarelto pre-trial rulings pending outcome of Supreme Court case.
Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?
Even after multiple bellweather wins, Janssen and Bayer still face claims they did not warn doctors about concomitant use with Plavix and aspirin; as case begins in Philadelphia, plaintiff's attorney tells jury the firms were 'silent,' while defense points to doctors' testimony that a different warning would not have changed their prescribing.
Product Liability Litigation Playbook: Pros And Cons For Pharma
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.